[ad_1]
Definitive Healthcare Corp. (NASDAQ:DH – Get Rating) has earned an average rating of “Buy” from the thirteen brokerages that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $37.00.
Several research firms have recently issued reports on DH. Canaccord Genuity Group raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research report on Thursday, February 24th. Canaccord Genuity Group raised Definitive Healthcare from a “hold” rating to a “buy” rating and cut their price objective for the company from $46.00 to $28.00 in a research report on Thursday, February 24th. Barclays decreased their target price on Definitive Healthcare from $26.00 to $23.00 in a research report on Thursday, February 24th. Credit Suisse Group reduced their price target on Definitive Healthcare from $30.00 to $24.00 and set a “neutral” rating on the stock in a research report on Thursday, February 24th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Definitive Healthcare from $21.00 to $26.00 and gave the company a “hold” rating in a research note on Tuesday, April 5th.
In other news, Director Jeffrey Charles Haywood sold 18,315 shares of the business’s stock in a transaction dated Wednesday, May 11th. The shares were sold at an average price of $15.46, for a total value of $283,149.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 17.52% of the stock is owned by company insiders.
A number of institutional investors have recently made changes to their positions in the stock. Advisor Group Holdings Inc. acquired a new stake in Definitive Healthcare during the third quarter valued at approximately $26,000. Geode Capital Management LLC bought a new position in Definitive Healthcare during the third quarter worth $3,904,000. Morgan Stanley acquired a new position in Definitive Healthcare in the third quarter worth $142,000. Royal Bank of Canada acquired a new position in Definitive Healthcare in the third quarter worth $656,000. Finally, Marshall Wace LLP bought a new stake in Definitive Healthcare during the third quarter valued at $314,000. 99.42% of the stock is owned by hedge funds and other institutional investors.
Shares of DH opened at $19.55 on Friday. The stock’s fifty day simple moving average is $20.70 and its 200 day simple moving average is $22.99. Definitive Healthcare has a twelve month low of $14.76 and a twelve month high of $50.30. The company has a quick ratio of 3.21, a current ratio of 3.21 and a debt-to-equity ratio of 0.18.
Definitive Healthcare (NASDAQ:DH – Get Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.02). The firm had revenue of $50.12 million during the quarter, compared to analyst estimates of $48.47 million. On average, sell-side analysts predict that Definitive Healthcare will post 0.1 earnings per share for the current year.
About Definitive Healthcare (Get Rating)
Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution.
Read More
Receive News & Ratings for Definitive Healthcare Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Definitive Healthcare and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link
